Key result
Post-repair TTVR yields ~89% rate of none or mild TR, comparable to primary TTVR.
Why the study?
Evidence remains limited regarding the safety and effectiveness of transcatheter tricuspid valve replacement (TTVR) for residual or recurrent tricuspid regurgitation after prior surgical or transcatheter tricuspid valve repair.
Does transcatheter tricuspid valve replacement (TTVR) after prior tricuspid valve repair provide similar safety and effectiveness compared to primary TTVR in patients with severe tricuspid regurgitation?
Observational (n=69)
Does transcatheter tricuspid valve replacement (TTVR) after prior tricuspid valve repair provide similar safety and effectiveness compared to primary TTVR in patients with severe tricuspid regurgitation?
In a registry subanalysis, transcatheter tricuspid valve replacement after prior surgical or transcatheter valve repair was technically feasible and demonstrated early safety, TR reduction, and functional improvements broadly comparable to primary TTVR.
May support post-repair TTVR feasibility in selected patients; leaves open durability versus primary TTVR in larger studies.
Background Transcatheter tricuspid valve replacement (TTVR) may be a promising option for patients with residual or recurrent tricuspid regurgitation (TR) after prior surgical or transcatheter tricuspid valve (TV) repair, but evidence in this setting remains limited. Purpose This study assesses the safety and effectiveness of TTVR after prior repair versus primary TTVR in patients with severe TR. Methods Between 2024 and 2026, consecutive patients with severe TR undergoing either primary TTVR or TTVR after prior TV repair were included in this subanalysis of the Berlin registry of right heart interventions. Clinical and procedural data were prospectively collected at the time of the procedure, at hospital discharge, and at 30–60 days of follow-up. Results In this subanalysis, 69 patients with TR were included, of whom 9 patients (13%) underwent post-repair TTVR after prior tricuspid valve intervention or repair (tricuspid transcatheter edge-to-edge repair [T-TEER] n=1, percutaneous annuloplasty [PA] n=7, and surgical TV repair n=1). Median age, proportion of women, and baseline NYHA class III/IV were 82 (68-84) years, 78%, and 78% in the post-repair TTVR group versus 80 (76-83) years, 65%, and 78% in the primary TTVR group, respectively. Procedural success was achieved in all patients. In-hospital mortality was 1%, with no procedure-related deaths. In-hospital adverse events included bleeding in 11% of patients with post-repair TTVR and 3% of patients with primary TTVR, vascular complications in 0% and 2%, new pacemaker implantation in 22% and 20%, stroke in 0% and 2%, myocardial infarction in 0% and 0%, thromboembolic events in 0% and 2% as well as acute kidney injury in 0% and 3%, respectively. At discharge, TR severity was markedly reduced and comparable between groups (none/mild TR: 89% in post-repair TTVR vs. 98% in primary TTVR). At follow-up, NYHA functional class improved in both groups without significant intergroup differences: 33% (post-repair TTVR) versus 45% (primary TTVR) in class I/II at follow-up (vs. 22% in both groups at baseline). During follow-up, heart failure rehospitalization occurred in 11% in the post-repair TTVR group versus 3% in the primary TTVR group. Conclusion In this hypothesis-generating subanalysis of the Berlin registry of right heart interventions, post-repair TTVR was technically feasible and showed a favorable early safety and performance profile. Outcomes were broadly similar to those observed after primary TTVR in patients with significant TR.
No takes yet. Share an insight, caveat, or question.
Mattig et al. (2026) conducted an observational in Severe tricuspid regurgitation (n=69). Post-repair transcatheter tricuspid valve replacement (TTVR) vs. Primary transcatheter tricuspid valve replacement (TTVR) was evaluated on Discharge TR severity (none/mild TR). Post-repair TTVR achieved 100% procedural success and comparable discharge TR reduction to primary TTVR (89% vs 98% none/mild TR).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: